| Twelve-Month Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation. |
|
Deok Bae Kim, Jae Hui Kim, Seong Hun Jeong, Tae Gon Lee, Jong Woo Kim, Chul Gu Kim, Sung Won Cho, Dong Won Lee, Jung Il Han |
1Happyeye21 Hospital, Gwangju, Korea.
2Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@daum.net |
| 망막혈관종성증식 환자에서 유리체강내 항혈관내피세포성장인자 주입술의 12개월 임상결과 |
|
김덕배1⋅김재휘2⋅정성헌2⋅이태곤2⋅김종우2⋅김철구2⋅조성원2⋅이동원2⋅한정일2 |
Happyeye21 Hospital1, Gwangju, Korea
Department of Ophthalmology, Kim’s Eye Hospital, Konyang University College of Medicine2, Seoul, Korea |
|
|
| Abstract |
PURPOSE
To evaluate the 12-month outcomes of anti-vascular endothelial growth factor (VEGF) treatment for patients with retinal angiomatous proliferation (RAP). METHODS: Retrospective review of medical records was performed for 33 patients (33 eyes) who were diagnosed with RAP. All patients were initially treated with three consecutive intravitreal anti-VEGF injections after diagnosis. Additional treatment was performed when the recurrence of exudation was noted. The best-corrected visual acuity (BCVA) was measured before the first injection and at 3, 6, and 12 months after the first injection. The value measured before the treatment was compared with those measured after treatment. RESULTS: The patients received an average of 4.2 +/- 1.7 intravitreal anti-VEGF injections during the 12-month follow-up period. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and at 3, 6, and 12 months after the first injections were 0.76 +/- 0.49, 0.55 +/- 0.35, 0.67 +/- 0.41, and 0.70 +/- 0.50, respectively. BCVA was significantly improved at 3 and 6 months (p < 0.001 and p = 0.037) compared to that measured before the first injection. However, there was no significant difference between BCVA before the first injection and 12 months after the first injection (p = 0.590). At 12 months of follow-up, 29 eyes (87.9%) showed stable (<2 log MAR lines of change) or improved (> or =2 log MAR lines of improvement) BCVA. CONCLUSIONS: Anti-VEGF therapy was found to be beneficial in both normalizing macular thickness and in improving or maintaining visual acuity in the majority of patients with RAP. |
| Key Words:
Anti-vascular endothelial growth factor;Clinical outcomes;Retinal angiomatous proliferation;Visual acuity |
|
PDF Links
Full text via DOI
Download Citation
